Chong Kun Dang Pharmaceutical (185750) — Capital Reinvestment Ratio
Chong Kun Dang Pharmaceutical (185750) has a Capital Reinvestment Ratio of 6.04x as of March 2026, meaning it reinvests 6% of its operating cash flow (₩12.32 Billion) in capital expenditures (₩74.34 Billion). Check Chong Kun Dang Pharmaceutical tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Chong Kun Dang Pharmaceutical Capital Reinvestment Ratio (2016–2025)
This chart tracks Chong Kun Dang Pharmaceutical's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see 185750 cash generation efficiency.
Annual Capital Reinvestment Ratio for Chong Kun Dang Pharmaceutical (2016–2025)
Year-by-year Capital Reinvestment Ratio for Chong Kun Dang Pharmaceutical from 2016 to 2025. See Chong Kun Dang Pharmaceutical free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 2.66x | ₩67.36 Billion | ₩179.13 Billion | ▲ +158.6% |
| 2024 | 1.03x | ₩64.29 Billion | ₩66.10 Billion | ▲ +375.4% |
| 2023 | 0.22x | ₩318.16 Billion | ₩68.81 Billion | ▼ -67.4% |
| 2022 | 0.66x | ₩67.73 Billion | ₩44.90 Billion | ▼ -82.3% |
| 2021 | 3.74x | ₩12.90 Billion | ₩48.24 Billion | ▲ +1095.0% |
| 2020 | 0.31x | ₩104.32 Billion | ₩32.64 Billion | ▲ +10.7% |
| 2019 | 0.28x | ₩77.29 Billion | ₩21.84 Billion | ▼ -45.0% |
| 2018 | 0.51x | ₩42.63 Billion | ₩21.92 Billion | ▲ +112.2% |
| 2017 | 0.24x | ₩81.67 Billion | ₩19.79 Billion | ▼ -64.5% |
| 2016 | 0.68x | ₩57.79 Billion | ₩39.44 Billion | — |